In a mouse model of pancreatic neuroendocrine cancer, the engineered immune cytokine PD1‐IL2v can induce the infiltration of stem cell‐like effector CD8+ T cells, leading to tumour regression and improved survival rates. This evidence concerns the gene CD8A and neoplasm.